Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study


29 Sep 2019


Poster Display session 2


Tumour Site

Hepatobiliary Cancers


AiPing Zhou


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


A. Zhou1, Y. Sun1, W. Zhang1, Z. Jiang1, B. Chen2, J. Zhao3, Z. Li3, L. Wang3

Author affiliations

  • 1 Internal Medicine, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN
  • 2 Radiotherapy, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN
  • 3 Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3159


The available treatment for advanced hepatocellular carcinoma (aHCC) remained limited in 2016 when our study was initiated. The phase II, ALTER0802 study (NCT02809534) evaluated anti-tumor activity and safety of anlotinib, a small molecular tyrosine kinase inhibitor (TKI), in patients (pts) with aHCC.


Pts aged 18-75 yrs with histologically/cytologically confirmed unresectable or metastatic HCC or prior progression/intolerance on standard therapy were enrolled if they were Child-Pugh ≤8 and ECOG PS ≤ 1. Pts were divided into two cohorts: 1. those who did not receive prior systemic chemo or targeted therapy; 2. those who have received prior TKI treatment. Pts received anlotinib 12 mg, 2 weeks on/ 1 week off, until disease progression or unacceptable adverse events (AEs). The primary endpoint was progression-free survival rate at 12 weeks (PFR12w); ORR, DCR, TTP, OS, PFR24w, and safety were secondary endpoints.


At the date of the interim analysis (Mar 7, 2019), 43 pts were enrolled (26 and 17 pts for cohort 1 and 2, respectively). In cohort 1, PFR12w was 80.8% (95%CI, 67.0-97.4); median OS (mOS) was 10.8 mo (months; 95%CI, 8.0-NE [not estimated]); median TTP (mTTP) was 5.5 mo (95%CI, 4.7-NE); DCR was 84.6% (95%CI, 65.1-95.6). In cohort 2, PFR12w was 58.8% (95%CI, 39.5-87.6); mOS was not reached; mTTP was 4.01 mo (95%CI, 1.94-11.4); DCR was 76.5% (95%CI, 50.1-93.2). Other outcomes for both cohorts were presented in the table. Overall, treatment related AEs (TRAEs) were limited to mild hypertention, hand-foot skin reaction and bone and muscular pain. No grade IV or above AEs occurred.Table:


Cohort 1 (n = 26)Cohort 2 (n = 17)
ORR (n)3.85% (1)5.9% (1)
CR (%)00
PR (%)1 (3.85)1 (5.9)
SD (%)21 (80.8)12 (70.6)
PD (%)4 (15.4)4 (23.5)
PFR24w (95%CI)43.2% (26.5-70.6)22.1% (10.5-55.8)


In this interim analysis, anlotinib showed durable anti-tumor activity and manageable toxicity in pts with aHCC regardless of in the first or second line treatment.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.


Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.